Saltar al contenido
Merck
Todas las fotos(3)

Documentos clave

Ver Toda la documentación

G6423

Sigma-Aldrich

Gemcitabine hydrochloride

≥98% (HPLC), powder, antitumor agent

Sinónimos:

2′-Deoxy-2′,2′-difluorocytidine; dFdC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula empírica (notación de Hill):
C9H11F2N3O4 · HCl
Número de CAS:
122111-03-9
Peso molecular:
299.66
Número MDL:
MFCD01735988
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329799951
NACRES:
NA.77

Nombre del producto

Gemcitabine hydrochloride, ≥98% (HPLC)

Nivel de calidad

100

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated
protect from light

solubilidad

H2O: ≥10 mg/mL

emisor

Eli Lilly

temp. de almacenamiento

room temp

cadena SMILES

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F

InChI

1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1

Clave InChI

OKKDEIYWILRZIA-OSZBKLCCSA-N

Información sobre el gen

human ... POLA1(5422) , POLA2(23649) , POLD1(5424) , POLD2(5425) , POLD3(10714) , POLD4(57804) , POLE(5426) , POLE2(5427) , POLE3(54107) , PRIM1(5557) , PRIM2(5558) , RRM1(6240) , RRM2(6241) , RRM2B(50484)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Gemcitabineis a pyrimidine nucleoside analog of deoxycytidine. It exhibits anticancereffects against various cancers.

Aplicación

Gemcitabinehydrochloride has been used as a chemotherapeutic agent to study its effects onthe human pancreatic adenocarcinoma cell lineIt has been used as a chemotherapeutic to study its resistance inpancreatic stellate cells (PSCs)It has also been used to study its effects on patient-derivedxenograft (PDX) organoids.

Acciones bioquímicas o fisiológicas

Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite.

Características y beneficios

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H360

Clasificaciones de peligro

Repr. 1B

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000302269
0000302269
0000174095
0000298874
0000408869

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yuan Chi et al.
Frontiers in oncology, 11, 671082-671082 (2021-12-07)
Pancreatic cancer is associated with poor prognosis and dismal survival rates. This study aims to investigate roles of lncRNA UCA1-loaded exosomes secreted by pancreatic stellate cells (PSCs) in Gemcitabine (Gem) resistance of pancreatic cancer under hypoxia, which involves the methylation
Abdullah Shopit et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 91, 153711-153711 (2021-08-28)
Gemcitabine (GCB) is a first-line chemotherapeutic drug for pancreatic cancer (PCa). However, the resistance begins developing within weeks of chemotherapy. SPINK1 overexpression enhances resistance to chemotherapy. In a recent study, our laboratory established that the oleanolic acid (OA) derivative, K73-03
M Barton-Burke
Cancer nursing, 22(2), 176-183 (1999-04-27)
There have been exciting new developments in anticancer therapy over the past few years. One such therapy uses gemcitabine (GemzarR), an antimetabolite approved in 1996 by the Food and Drug Administration (FDA) for first-line treatment of locally advanced (nonresectable stage
Isabel Romero-Calvo et al.
Molecular cancer research : MCR, 17(1), 70-83 (2018-09-02)
Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great promise for understanding the biological underpinnings of disease and advancing therapeutic precision medicine. Despite the increased use of organoids, the fidelity of molecular features, genetic heterogeneity, and drug response to the
Erez Hasnis et al.
Neoplasia (New York, N.Y.), 16(6), 501-510 (2014-06-25)
Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration
Ver todos los artículos relacionados

Artículos

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico